Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Daiichi Sankyo: Enhertu significantly improves progression-free survival in HER2‑mutated NSCLC

In the phase‑3 DESTINY‑Lung04 trial, Enhertu as first‑line therapy for HER2‑mutated non‑small‑cell lung cancer showed a significantly longer progression‑free survival (median 14.3 vs. 8.3 months) and reduced the risk of progression or death by 37% (HR 0.63) versus pembrolizumab plus chemotherapy. The objective response rate was 70% versus 44.5%, with median duration of response 13.4 versus 9.7 months. The safety profile was consistent with prior knowledge; treatment‑related grade‑3 events occurred in 34.1%, and interstitial lung disease/pneumonitis in 20.8% with four grade‑5 cases. » More on de.investing.com
Daiichi Sankyo rises after partner Merck reports positive study result

Daiichi Sankyo’s shares gained 6.1% after Merck, in partnership with Moderna, reported positive results for a personalized skin cancer vaccine in a late-stage trial. Daiichi was not directly involved in that specific study but benefited from improved sentiment toward Merck, Moderna and their global partners. The price increase helped lift the Nikkei 225 and highlights Daiichi’s sensitivity as a leading Japanese developer of cancer therapies to industry news. » More on de.investing.com
Daiichi Sankyo: CHMP recommends approval of Enhertu for HER2-positive solid tumors

The CHMP of the EMA has recommended approval of Enhertu (trastuzumab deruxtecan) for adult patients with inoperable or metastatic HER2-positive solid tumors. The recommendation is based on three phase II studies showing confirmed objective response rates of about 47–52% and a median duration of response of 5.5 to 14.2 months. The safety profile was consistent with earlier trials; neutropenia, anemia and pneumonic events were observed. The final decision now rests with the European Commission. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Daiichi Sankyo has already paid €0.21 in dividends. The last payout was in June.

Financials

In the last quarter, Daiichi Sankyo had revenue of €3.1bn and net profit of €369.77m

(EUR)	June 2026	YoY
Revenue	3.1bn	10.58%
Gross profit	2.43bn	7.61%
Net profit	369.77m	26.69%
EBITDA	573.84m	15.06%

Fundamentals

Metric	Value
Market capitalization	€29.18bn
Number of shares	1.82bn
52-week high/low	€23.26 - €13.60
Dividend yield	2.65%
Dividends TTM	€0.43
Beta	0.80
P/E ratio	21.33
PEG ratio	-1.33
P/B ratio	3.01
P/S ratio	2.31

Company profile

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Name	Daiichi Sankyo
CEO	Hiroyuki Okuzawa
Headquarters	Tokyo, ty Japan
Website	daiichisankyo.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	04/01/2000
Employees	20,171